Abstract 470P
Background
Glioblastoma multiforme (GBM) is the most common malignant brain tumor. MRPs are involved in mitochondrial translation, with previously revealed role in cancer. Here we aimed to understand their role in GBM.
Methods
Differentially expressed genes (DEGs) were identified through the ‘DESeq2' on R and GEO2R. Survival analysis with optimal expression cutoff for Overall Survival (OS) and median cutoffs for Disease-Free Survival (DFS) based on TCGA-GBM was done using the ‘survival' and 'survminer' R packages, and GEPIA2 online tool. Gene Set Enrichment Analysis (GSEA) was performed using Enrichr tool. miRNA-mRNA networks were constructed using MultiMiR and CytoScape. Immune and methylation analyses were conducted using TIMER2.0 (XCELL) and cBioPortal.
Results
OS estimates indicated worse survival in patients with higher expression of selected MRPs (Table). Further analysis indicated that elevated expression of MRPS33 and MRPL23 is correlated with decreased DFS, with Hazard Ratios (HRs) of 1.80 (p = 0.0012) and 1.70 (p = 0.0039), respectively. GSEA on upregulated genes in high MRPS33-expressers revealed relations to PDGF, NCAM1 interactions, EMT, and integrins in angiognesis. miRNA-mRNA network has identified hub miRNAs, like hsa-miR-1-3p, to have validated interactions with MRPs of interest. Expression of MRPL41, MRPL35, and MRPS33, had negative correlations with HM27/HM450 methylation (Spearman's rho = -0.41, -0.20, and -0.19, respectively; p < 0.05). Finally, there was a positive correlation between MRPS33 expression and Macrophage M2 infiltration in GBM (rho = 0.393, p < 0.05). Table: 470P
Selected MRPs gene expression and GBM patient survival, HR > 1 suggests a harmful effect of the gene on survival
Gene | HR | P Value | 95% CI | DE |
MRPL41 | 1.732784 | 0.0047 | (1.35, 2.11) | D |
MRPL32 | 1.946699 | 0.0010 | (1.55, 2.34) | U |
MRPL17 | 1.787801 | 0.0070 | (1.37, 2.21) | U |
MRPL23 | 1.689083 | 0.0103 | (1.29, 2.09) | U |
MRPS33 | 1.58498 | 0.0226 | (1.19, 1.98) | U |
DE: Differential expression (GBM relative to normal) across GSE4290, GSE68848, and TCGA-GBM (overlap); U: Upregulated; D: Downregulated.
Conclusions
Our study identified a complex multi-omic framework through which MRPs are regulated and play their prognostic and tumorigenic roles in GBM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
457P - Progression-free survival 2 (PFS2) as a surrogate for overall survival in a multicentric real-world data cohort of glioblastoma (GBM)
Presenter: Jesus Yaringaño Cerna
Session: Poster session 16
458P - Patterns of care and clinical outcomes of patients with glioblastoma in the United States from 2005-2020: A real-world analysis
Presenter: Diya Jayram
Session: Poster session 16
459P - Association of tumor treating fields device usage with survival in newly diagnosed GBM: A real-world analysis of patients in the US
Presenter: Jennifer Connelly
Session: Poster session 16
460P - Exploring the efficacy and optimal timing of tumor treating fields in newly diagnosed glioblastoma: A real-world study
Presenter: Zelei Dai
Session: Poster session 16
461P - Effectiveness of dabrafenib-trametinib and larotrectinib in adult recurrent glioblastoma patients: A real-life cohort analysis from 3 Italian centers
Presenter: Marta Padovan
Session: Poster session 16
462P - Regorafenib for relapsed glioblastoma: Retrospective real-world analysis of a single Institution experience
Presenter: Giulia Rovesti
Session: Poster session 16
463P - Real-world outcomes of patients with non-small cell lung cancer with and without intracranial metastatic disease: A retrospective cohort analysis
Presenter: Madison Sherman
Session: Poster session 16
465P - Surgical intervention association with the development of subsequent dissemination in childhood diffuse intrinsic pontine gliomas (DIPG)
Presenter: Shoaib Bashir
Session: Poster session 16
Resources:
Abstract
466P - Re-irradiation therapy for pediatric brainstem tumours: 20 years of clinical experience
Presenter: Olga Regentova
Session: Poster session 16
Resources:
Abstract
467P - Temozolomide potentially postpones the development of subsequent metastases in pediatric diffuse intrinsic pontine glioma (DIPG) patients
Presenter: Shoaib Bashir
Session: Poster session 16
Resources:
Abstract